1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Surface-Active Agents: new trials by email Literature Review of Surface-Active Agents trials Research Report on Surface-Active Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo - Respiratory Distress Syndrome, Newborn, Premature Birth | Phase 2 | Terminated | Windtree Therapeutics | 136 | 2005-02-01 | 2012-06-13 |
Bronchopulmonary Dysplasia (1) · Premature Birth (1) · Respiratory Distress Syndrome, Newborn (1)
United States (1)
Carlos Guardia, MD (1) · Matthew M Laughon, MD, MPH (1)